valu usd unless otherwis note
valuat support upgrad op
view see resili privat label over-the-counter drug/self-
care busi demand current health
pandem share gain lower price store brand offer
see result econom downturn stock yet
diverg averag valuat seen upward
move stapl compani think leav rel
upsid upgrad op
consum over-the-counter busi revenu see rel
stabil current environ three reason demand
stapl gener steadi ii drug focu could see greater demand
given concern stock iii prior econom
downturn driven privat label over-the-counter market share higher
us leader emerg
structur shift on-lin would amplifi e-commerc busi
small million grow sku on-lin
think stock gotten credit posit
specif lay five chart exhibit speak posit
overal direct align
stapl stock us would make sens
environ stock trade in-lin rel price-to-earnings
averag push toward upper end rang
toward pariti valuat impli upside/rel spread
direct think share go perceiv safeti stapl
name sinc sell-off exhibit
think gap partial close
lower ep conserv gener rx
assumpt rx compris total revenu move lower
nevertheless reduc ep lower gener
revenu margin larg lack visibl around impact relat
captur downsid scenario busi
see sector stress test report link scenario analysi howev
leav consum forecast year
unchang stock histor trade core us consum
busi see rel stabil
resolut tax litig year repres meaning
opportun view option drill background/
set-up follow expert tax call link work
litig irish tax author ir
overhang next data point irish high court hear
per expert yesterday could well move push
possibl catalyst also somewhat binari event
dissemin produc price prior trade day market close estimate unless otherwis note
stabl long-term outlook well posit current
unknown environ attract rel posit
see demand underli product unlik
materi impact move econom downturn
recess lower price price store brand portfolio
over-the-counter product potenti pick market share past
downturn final view tax overhang like lift
year improv financi flexibl
driver thesi
organ csca growth like remain lower level
near term base busi eros like remain
overal see stabl revenu growth
csci oper margin expans continu
next year offer addit ep support
gener rx still expect separ time
seem unclear assum remain consolid
valuat like dictat valu market
place remain-co consum busi
think rel see appreci
given rel posit current downturn
upsid risk success separ sale rx
drive premium asset acceler new launch
activ across over-the-counter rx fda approv new larg
over-the-counter categori switch favor quicker-than-
expect resolut irish tax disput ir nopa
downsid risk slowdown core csca revenu
impact overal busi assum
greater dis-synergy/dilut rx separ
expect unfavor outcom irish us tax
upcom potenti catalyst updat around spin
potenti bolt-on accret use
capit clariti tax issu
bloomberg capit market estim upside/downside/target
base-cas scenario see stock impli
price-to-earnings ep
low-single-digit growth csca driven larg
recent oral self-car acquisit annual flattish
declin oper margin across platform near-
term driven step-up invest return growth
time
debt pay-down excess cash share repurchas
linger overhang irish tax disput ir nopa
weigh share price
upsid case scenario see stock impli
price-to-earnings ep
mid-single-digit better organ revenu growth
oper margin expans across platform
debt pay-down excess cash re-introduc accret
favor resolut irish ir tax disput
downsid scenario see stock impli
price-to-earnings pro forma ep
step-up invest fail pay contribut lower
oper margin time
model
particularli rx
closer look chart help tell set-up stori watch
chart relat sell-off thu far close track
stapl peer expect see increas consum demand sinc februari
trade versu look three stapl compani
could view beneficiari includ campbel soup compani procter
gambl collect move higher drive spread exhibit
call expect pariti perform perceiv larg global flight-to-qu
household name direct think correl better
group given privat label over-the-counter portfolio notabl concentr area
over-the-counter medicin infant formula would expect demand
exhibit perform sinc feb versu beneficiari index pg
chart lost histor premium trade sinc
averag rel valuat current think rel
valuat increas given compani defens earn power
environ argu break last four year rang return
histor averag growth slow justifi rel valuat
step exhibit howev argu current environ
earn base defend trend toward upper end
rang seen last sever year would impli move higher roughli
in-lin potenti upsid target
exhibit trade line rel averag believ
garner premium defens posit current market
chart valuat rel highli correl organ
us consum csca revenu growth highli focus perform
segment exhibit also skeptic came last quarter still
convinc full turnaround given margin pressur link last coupl year
concern valid margin asid see improv top-lin growth
guidanc full year versu guid
conserv stanc gener rx busi importantli think
adjust host downward revis across variou compani
full year due visibl perrigo us consum busi hold
reason well stock histor react perform core busi
cours assumpt consum continu buy buy
lower price store brand over-the-counter product cough cold medicin allergi
infant formula
exhibit prgo rel valuat correl organ growth
us consum csca busi defend environ
chart past analog help downturn reliabl first
go back econom downturn time challeng given small size
billion revenu mix busi look downturn
challeng well time period saw meaning outperform
also start allergi brand store brand over-the-counter switch ie
zyrtec/cetirizin went decemb also one busier year
bolt-on deal compani
exhibit perform well rel help over-the-counter store
brand switch bolt-on
chart past analog help true late mislead given
host company-specif challeng compani brought fourth ceo less
year began former ceo papa left april two follow
announc current ceo murray kessler octob follow guidanc cut
next month due pre-dat challeng rx busi unexpect tax
call irish tax author estim billion still litig
word stock meaning under-perform host company-specif
challeng make real compar imposs
exhibit late weak driven host company-specif factor
decemb re-set ep novemb announc unexpectedirish tax liabil per share decemb
exhibit segment build
 segment build self-car ranir sale million synergi exp gross distribut oper oper per management flattish margin bc investmentssal growth stop declin revers futuredistribut sg mix profit mix incom mix self-car inclus ranir intenational gross ranir lower gm intenational rest biz neutral omdistribut oper oper sale growth ranir gmdistribut sg expans next year sale mix profit mix incom mix
exhibit segment build cont
 segment build y/i growth vs gross distribut oper oper y/i growth vs meaning declin sale growth sg mix profit mix incom mix corpor cost across platform
exhibit forecast
 incom self-car consum self-car prescript y/i growth vs total revenu net sale growth organ growth growth y-i growth driven acquisitionscost total gross profit gross portion invest dsg oper incom excl invest close target oper incom incom tax provis incom net incom ep non-gaap adj dilut ep share fulli dilut share ebitda ebitda analysi growth beyondadjust net margin expens net incom pharmaceuticals/specialti
price target base blend price-to-earnings ev/ebitda multipl use cy
estim assum multipl respect taken histor
averag global consum multipl price-to-earnings ev/ebitda made adjust
base company-specif attribut private-label discount earn momentum gener
busi discount litig risk collect result valuat discount
impli return price target support outperform rate
risk rate price target
organ revenu growth consum self-car america segment soften due
weaker-than-expect over-the-counter market growth greater-than-expect price eros
delay fda approv gener drug applic result declin revenu and/
margin rx segment
unexpect meaning competit entri us store brand over-the-counter rx busi
lead store-brand over-the-counter manufactur us market share compani
also particip pharmaceut market domest intern
omega deal ad ex-u exposur often compar larg global
manufactur realiti direct comp given diversifi busi model
encompass consum healthcar brand consum healthcar rx compani
acquir brought lower tax structur royalti stream tysabri sold
royalti pharma set platform intern expans
